Cited 0 times in
Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이승규 | - |
dc.contributor.author | 최은영 | - |
dc.date.accessioned | 2021-01-19T07:57:18Z | - |
dc.date.available | 2021-01-19T07:57:18Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 0392-856X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/181390 | - |
dc.description.abstract | Objectives: To compare the occurrence of non-infectious uveitis based on the type of tumour necrosis factor (TNF) inhibitor used to manage spondyloarthritis in ankylosing spondylitis (AS) patients. Methods: The occurrence (new-onset and recurrence) of uveitis was reviewed retrospectively in AS patients receiving different TNF inhibitor therapies (adalimumab [ADA], infliximab [IFX], etanercept [ETN], and golimumab [GOL]) for the management of spondyloarthritis from 2005 to 2018. Kaplan-Meier analysis was performed to calculate the cumulative occurrence rates of uveitis during TNF inhibitor therapy, and a log-rank test was used to analyse differences between the survival curves. Multivariable Cox proportional-hazards models were used to compute hazard ratios (HRs) of different TNF agents for uveitis occurrence after adjusting for concurrent confounding factors. Results: The three-year cumulative occurrence rates of uveitis were significantly different according to the type of anti-TNFs used (23.1% in IFX, 18.5% in ETN, and 11.9% in ADA+GOL group) (p=0.020). The risk of new-onset uveitis was similar for different drugs. However, the IFX group showed a 5.4 times higher risk of recurrence than the ADA+GOL group (p=0.022). After adjusting for other confounding factors, IFX use was independently associated with a more frequent occurrence of uveitis in AS patients (HR=2.01; p=0.011). Conclusions: A significant number of AS patients who received anti-TNF therapy developed uveitis. Different types of anti-TNF drugs were associated with uveitis recurrence. Particularly, chimeric mouse-human monoclonal antibody (IFX) was found to increase the risk of uveitis occurrence compared to humanised monoclonal antibody (ADA or GOL). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Clinical And Experimental Rheumatology S.A.S | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adalimumab / adverse effects | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Etanercept / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infliximab / adverse effects | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Spondylitis, Ankylosing* / drug therapy | - |
dc.subject.MESH | Tumor Necrosis Factor Inhibitors / adverse effects* | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha | - |
dc.subject.MESH | Uveitis* / chemically induced | - |
dc.title | Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학교실) | - |
dc.contributor.googleauthor | Eun Young Choi | - |
dc.contributor.googleauthor | Minwoo Lee | - |
dc.contributor.googleauthor | Christopher Seungkyu Lee | - |
dc.contributor.localId | A02913 | - |
dc.contributor.localId | A05056 | - |
dc.relation.journalcode | J00555 | - |
dc.identifier.eissn | 1593-098X | - |
dc.identifier.pmid | 32828140 | - |
dc.identifier.url | https://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=32828140 | - |
dc.contributor.alternativeName | Lee, Christopher Seungkyu | - |
dc.contributor.affiliatedAuthor | 이승규 | - |
dc.contributor.affiliatedAuthor | 최은영 | - |
dc.citation.volume | 38 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1132 | - |
dc.citation.endPage | 1137 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol.38(6) : 1132-1137, 2020-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.